NextCure Business Summary

NextCure, Inc. (NXTC) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, research collaborations, and private placements, as it currently lacks FDA-approved products for commercial sale. The company’s business model is centered on the discovery and development of first-in-class immunotherapies, with primary business segments focused on Antibody-Drug Conjugates (ADCs) and novel immune checkpoint inhibitors. Its lead clinical pipeline includes SIM0505, a CDH6-directed ADC co-developed with Simcere Zaiming, and LNCB74, a B7-H4-targeted ADC, both of which are undergoing Phase 1 dose-escalation trials as of early 2026. NextCure competes directly with oncology-focused biotechs such as Nurix Therapeutics, Mersana Therapeutics, and Sutro Biopharma, positioning itself as a specialized player in the high-growth ADC market by targeting niche, clinically validated pathways like B7-H4 and CDH6 to address solid tumors resistant to standard checkpoint inhibitors. The company was co-founded by President and CEO Michael Richman and world-renowned immunologist Dr. Lieping Chen. Richman brings over 30 years of industry experience, having previously served as CEO of Amplimmune (acquired by MedImmune) and COO of MacroGenics, while Dr. Chen is a pioneer in the PD-1/PD-L1 pathway and a professor at the Yale School of Medicine. The current leadership team includes Chief Operating Officer Timothy Mayer, Ph.D., and Chief Medical Officer Udayan Guha, M.D., Ph.D., both of whom possess extensive pedigrees in translational research and clinical development. NextCure is supported by a robust roster of institutional investors and board members, including Chairman David Kabakoff, Ph.D. of Sofinnova Investments, alongside significant positions held by Canaan Partners, OrbiMed, and Pfizer Inc.